Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism
ConclusionsEtelcalcetide effectively maintained serum iPTH, calcium, and phosphate levels in appropriate ranges with concomitant medications for SHPT for 52 weeks in Japanese hemodialysis patients, and was safe and well tolerated.Registration NumberJapicCTI-142665.
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
More News: Calcium | Chronic Kidney Disease | Dialysis | Hemodialysis | Hormones | Hyperparathyroidism | Japan Health | Study | Urology & Nephrology